Related references
Note: Only part of the references are listed.Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
Danae A. Delivanis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
General and Specific Genetic Polymorphism of Cytokines-Related Gene in AITD
Chen Xiaoheng et al.
MEDIATORS OF INFLAMMATION (2017)
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Ichiro Yamauchi et al.
THYROID (2017)
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Hyunju Lee et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Nivolumab induced myxedema crisis
Uqba Khan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review
Marie-Lea Gauci et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
D. L. Morganstein et al.
CLINICAL ENDOCRINOLOGY (2017)
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Alexander Faje
PITUITARY (2016)
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series
Patrizio Caturegli et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review
M. N. Joshi et al.
CLINICAL ENDOCRINOLOGY (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
FUTURE ONCOLOGY (2016)
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
Jeroen de Filette et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Maria Fleseriu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
Stefan R. Bornstein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Genetic risk factors for type 1 diabetes
Flemming Pociot et al.
LANCET (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies
Steven Orlov et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
Le Min et al.
CLINICAL CANCER RESEARCH (2015)
Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes
Asa K. Davis et al.
DIABETES CARE (2015)
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Frederique Albarel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Jane L. Chiang et al.
DIABETES CARE (2014)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2014)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Designing Therapeutic Clinical Trials for Older and Frail Adults With Cancer: U13 Conference Recommendations
Arti Hurria et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Adrenal insufficiency
Evangelia Charmandari et al.
LANCET (2014)
Blockade of the Programmed Death-1 (PD1) Pathway Undermines Potent Genetic Protection from Type 1 Diabetes
Nora M. Kochupurakkal et al.
PLOS ONE (2014)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement
Jacqueline Jonklaas et al.
THYROID (2014)
The ineligible patient: how to treat patients not included in clinical studies
Frances J. Mao et al.
WORLD JOURNAL OF UROLOGY (2014)
Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus
Eiji Kawasaki et al.
JOURNAL OF DIABETES INVESTIGATION (2014)
Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis
Le Min et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
Yan Feng et al.
CLINICAL CANCER RESEARCH (2013)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Le Min et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Mechanisms of PDL-1 mediated regulation of autoimmune diabetes
Indira Guleria et al.
CLINICAL IMMUNOLOGY (2007)
Autoimmune hypophysitis
P Caturegli et al.
ENDOCRINE REVIEWS (2005)
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma
K Sanderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice
MJI Ansari et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
H Ueda et al.
NATURE (2003)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
